State news

Maker of drug to treat opioid addiction agrees to settlement

State Attorney General William Tong has announced a $300 Million multistate settlement with a company  to settle allegations that it falsely and aggressively marketed and otherwise promoted the drug Suboxone, resulting in improper expenditures of state Medicaid funds.

Indivior, a Delaware company, will pay a total of $300 million to resolve various civil fraud allegations impacting Medicaid and other government healthcare programs. Connecticut will receive $7.9 million in the settlement and an additional $200,000 for Connecticut Department of Social Services’ state-funded programs.

Tong says this settlement sends a strong message that states across the nation are united in taking aggressive action against those who fraudulently and callously contributed to the opioid epidemic.

Suboxone is a drug product approved for use by recovering opioid addicts to avoid or reduce withdrawal symptoms while they undergo treatment. Suboxone and its active ingredient, buprenorphine, are powerful and addictive opioids. The settlement resolves allegations that, from 2010 through 2015, Indivior, directly or through its subsidiaries:

The civil settlement resolves the claims against Indivior brought in six qui tam lawsuits pending in federal courts in the Western District of Virginia and the District of New Jersey.


Now Playing

Rock Facebook

 

Weather

BID 2 BUY

Artist Profile

Concert Calendar

Community Calendar